CD274 and neoplasm: In the KEYNOTE-042 trial, pembrolizumab improved OS versus placebo in patients with previously untreated locally advanced or metastatic NSCLC and a PD-L1 tumour proportion score (TPS) of ≥ 1%, and approval was extended to this population [15].